{"schema_version":"secwatch.filing_event.v1","accession":"0000784199-25-000069","form_type":"8-K","ticker":"AORT","cik":"0000784199","company_name":"ARTIVION, INC.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.258958+00:00","generated_at":"2026-05-22T19:51:43.099470+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance","bullets":["Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.","Non-GAAP net income $2.5M ($0.06 diluted); adjusted EBITDA $17.5M (+1% YoY).","Product growth: stent grafts +14%, On-X +10%, BioGlue +7%; preservation services -23% from cyber backlog.","FY 2025 guidance raised: revenue $423-435M (11-14% constant currency growth); adj. EBITDA $84-91M.","Positive 30-day NEXUS data (63% MAE reduction); PMA submitted for AMDS Hybrid Prosthesis to FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0000784199-25-000069","json":"https://secwatch.observer/filing/0000784199-25-000069.json","markdown":"https://secwatch.observer/filing/0000784199-25-000069.md","text":"https://secwatch.observer/filing/0000784199-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/784199/000078419925000069/0000784199-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/784199/000078419925000069/aort-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T19:51:43.099470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}